Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y₁₂ inhibitor than among those who received triple therapy with warfarin, a P2Y₁₂ inhibitor, and aspirin. Dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. (Funded by Boehringer Ingelheim; RE-DUAL PCI ClinicalTrials.gov number, NCT02164864 .).